Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 601–700 of 704
Safety profile of pharmacotherapy in paitionts with non-alcogolic fatty liver disease
Peresada, E., Seliverstov, P. V., Вавилова, Т. В., Башарин, В. А., & Радченко, В. Г. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-3-69-75 · Cited by 1
Галкін, Б. М., & Філіпова, Т. О. (2020) · Microbiology&Biotechnology · doi:10.18524/2307-4663.2020.2(49).211285 · Cited by 1
Pharmaceutical significance and recent developments in utilizing bacterial enzymes
Vulichi, S. R., Kumar, R., Chippada, A. R., Sistla, D. S. M., Chunduri, V. R., Kapur, S., & Galla, K. M. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821406-0.00009-6 · Cited by 1
Microbial metabolites in nutrition and healthcare
Sundar, K., & Prabu, T. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824523-1.00012-2 · Cited by 1
Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii
Nycz, J., & Zajdel, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2021-0009 · Cited by 1
“Należy zwrócić uwagę, że dieta bogata w aminokwas – argininę – może zapobiegać indukcji operonu cgr [75, 76, 77].”
Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota
Velikova, T. V., Nakov, R., & Ianiro, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00074-7 · Cited by 1
Yan, A. (2015) · MacSphere (McMaster University) · doi:10.71548/4409 · Cited by 2
Proteobacteria drive significant functional variability in the human gut microbiomePreprint
Bradley, P. H., & Pollard, K. S. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/056614 · Cited by 1
Gut bacteria can stop cancer drugs from working
Reardon, S. (2017) · Nature · doi:10.1038/nature.2017.22109 · Cited by 1
Okumuş, B., Pedraza, J. M., & Bakshi, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1146729 · Cited by 1
Schmitz, M. A., Dimonaco, N. J., Clavel, T., & Hitch, T. C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596415 · Cited by 1
Microbial-Derived Exerkines Prevent Skeletal Muscle AtrophyPreprint
Valentino, T. R., Burke, B. I., Kang, G., Goh, J. Z., Dungan, C. M., Ismaeel, A., Mobley, C. B., Flythe, M. D. D., Wen, Y., & McCarthy, J. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596432 · Cited by 2
A widespread gut bacterial lineage distinguished by redox metabolism and phage defensePreprint
Noecker, C. A., Guo, L., Daté, C., Rai, N., Daramy, F., Hernandez, L. A. R., Kyaw, T. S., Trepka, K. R., Gupta, C. L., Ha, C. W. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.31.715625 · Cited by 1
Self-citationProteomics of E.coli Nissle 1917 in Responce to Cocos nucifera sap and Wine
Chandrasekhar, K., & Kumari, J. P. (2015) · International Letters of Natural Sciences · doi:10.18052/www.scipress.com/ilns.41.1
Inflammation and Antimicrobial Defense in the Intestine
Caballero, S., & Pamer, E. G. (2015)
Morgan, X. C., & Huttenhower, C. (2014)
Kinross, J. K., & Marchesi, J. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800344-2.00009-4
Biotransformation by the Gut Microbiome
Chi, L., & Lü, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64268-x · Cited by 1
Dietary Impacts on the Composition of Microbiota in Human Health and Disease
Verma, A. K., Kumari, R., Bhattacharya, A., & Paul, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-5708-3_21
Cong, J., Zhu, J., Zhang, C., Li, T., Liu, K., Liu, D., Zhou, N., Jiang, M., Hou, H., & Zhang, X. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/331876
Mythen, S. M. (2018) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Chemistry and Enzymology Encoded by the Human Microbiome
Shine, E. E., Nwe, P.-K., & Crawford, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14659-1
Soto-Perez, P., Bisanz, J. E., Berry, J. D., Lam, K. N., Bondy‐Denomy, J., & Turnbaugh, P. J. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3363840
Self-citationDarm-Herz-Achse: Wie Darmbakterien kardiovaskuläre Erkrankungen beeinflussen
Bartolomaeus, H., McParland, V. J., & Wilck, N. (2020) · Herz
Comprehensive Gut Microbiota and Drug Processing
Selber‐Hnatiw, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00104-2
Interplay between gut bacteria and Parkinson’s disease medication
van Kessel, S. P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182831964
Mikrobiomanalysen: Welchen Sinn haben sie für die Praxis?
Gorkiewicz, G. (2021) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-021-00116-7
“Eine Messung dieser Bakterien im Stuhl ermöglicht somit eine Aussage über die Effektivität der Pharmakotherapie [16, 17].”
BackgroundImpact of the Microbiome on Oral Biopharmaceutics
McCoubrey, L. E., Batchelor, H. K., Basit, A. W., Gaisford, S., & Orlu, M. (2021) · Wiley eBooks · doi:10.1002/9781119678366.ch17 · Cited by 1
Loss, E. O., Thompson, J. C., Cheung, K. P., Qian, Y., & Venturelli, O. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.08.487701
Satsangi, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732845043.793569708
Satsangi, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727604769.793569706
Cotter, P. D., & Barton, W. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726708065.793567416
Effect of Intestinal Flora on Composition of Urinary Calculi
周, 亚. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.126776
Protein-bound uremic toxins: putative modulators of calcineurin inhibitor exposure
Koppe, L., & Soulage, C. O. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac229
Interaction of Gut Microbiota with MedicationsPreprint
Liu, M., Xu, J., Jin, Q., & li, Y. (2022) · doi:10.22541/au.166523763.34733996/v1
Microbiome therapeutics as an alternative to the antibiotics
Singh, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00004-5
Hatzios, S. K. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01369-4
Rodents consuming the same toxic diet harbor a unique taxonomic and functional core microbiomePreprint
Stapleton, T. E., Lindsey, L. M., Sundar, H., & Dearing, M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3419959/v1
Intestinal Microbiome and Its Impact on Metabolism and Safety of Drugs
Chu, X. Y., & Ho, P. C. (2023) · Wiley eBooks · doi:10.1002/9781119660699.ch25 · Cited by 1
The Gut Microbiome, Microbial-Produced Pro-inflammatory Neurotoxins, and Neurological Disorders
Prasad, M., Rajagopal, P., & Jayaraman, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_8 · Cited by 2
A Potential Role of Xenometabolites as Nutraceutical: A Concurrent Review
Biswas, S., Imran, A., Islam, F., Arshad, M. U., Aslam, I., Shah, M. A., Shehzadi, U., Usman, I., Rasool, Z. F. U., & Aslam, S. (2024) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.12.1.02
Metabolic transformations catalyzed by gut microbiota
Ashton, M., Groundwater, P. W., Stocker, S., & Todd, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99133-9.00003-6
Amend, L., Huang, K. D., Sivapornnukul, P., Rabenow, M., Bielecka, A. A., Wang, X., Neumann‐Schaal, M., Witte, T., & Strowig, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.31.605913 · Cited by 1
“Prominent examples are the metabolism of digoxin, affecting its efficacy [4] , and checkpoint inhibitors, which display reduced activity in the absence of co-stimulating microbes [5] .”
BackgroundAnwar, H., Mukhtar, I., Muzaffar, H., Irfan, S., Saleem, S., & Ijaz, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_2 · Cited by 1
Overview of human microbiome and drug discovery
Dable-Tupas, G., Golingay, R., Veerapan, V., Almas, M. H., Deepika, R., Sonavika, G. S., Parmar, I., Joseph, C., Patel, S. N., & Lohani, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00014-1
The human microbiome and its expanding role in health and pharmacology
Kakad, A. A., Ingle, R. A., Nimse, A. M., Giram, R. D., & Nagrik, S. U. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.020
Silva, L. H. A. C., de Sales-Neto, J. M., Soares, M. M., Ferreira, D. A., Medeiros, A. B. A., & Rodrigues‐Mascarenhas, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124132
“Some molecules, such as arginine, can inhibit the conversion of digoxin to inactive forms [95,97], required for the growth of E. lenta [100].”
Systems Biology and Integrative Omics Decoding Xenobiotic Metabolism in Environmental Carcinogenesis
El-Sayed, W. M., Hassan, Y. M., Gwidah, H. A., Shalaby, A., Mahmoud, M. S., Waly, M. M., Mohamed, A. S., Hassan, Y. M., & Abdelgilil, M. E. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-2165-3.ch003
Meddling gut bacteria get in the way of drug therapy
Wilson, I. D. (2013) · doi:10.64628/ab.wddt4ytex
Decoding the Influence of Gut Microbial Enzymes on Drug Metabolism: Insights and Strategies
Palanisamy, H., & Vidyalakshmi, S. (2025) · Biology Bulletin Reviews · doi:10.1134/s2079086425600419 · Cited by 2
“The cardiac glycoside reductase operon in Eggerthella lenta was found to inactivate digoxin before its absorption (Haiser et al., 2014; Haiser et al., 2013). β -Glucosidase is one of the hydro-Fig”
Liu, W., An, M., Wang, Q., Liu, Y., Shang, Y., Dong, X., Ding, H., Fu, S., Han, X., & Shang, H. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2569789
Eggerthella lenta: A rare cause of septic shock and sepsis after Fournier's gangrene
Chen, L., Chen, Y., Lian, Y., Kong, L., Zhang, Y., Ma, Y., Zhang, S., Wang, X., Waheed, Y., & Ahmad, I. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108270
Gut microbiota impact on drug metabolism, bioavailability, and biotransformation
Boyle, N. R., & Patterson, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29289-7.00019-9
Tryptophan metabolite indole-3-acetate: a new culprit in irinotecan-induced gut epithelial injury
Fidelle, M., & Zitvogel, L. (2025) · Gut · doi:10.1136/gutjnl-2025-336758
Ganamurali, N., & Sabarathinam, S. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.107055
Baud, G., Prasad, A., Ellegaard, K., & Engel, P. (2024) · Figshare · doi:10.6084/m9.figshare.24779359
van Kessel, S. P., de Jong, H. R., Winkel, S. L., van Leeuwen, S. S., Nelemans, S. A., Permentier, H. P., Keshavarzian, A., & Aidy, S. E. (2020) · Figshare · doi:10.6084/m9.figshare.13115487
Muller, E., Algavi, Y. M., & Borenstein, E. (2021) · Figshare · doi:10.6084/m9.figshare.16800610
Baud, G., Prasad, A., Ellegaard, K., & Engel, P. (2024) · Figshare · doi:10.6084/m9.figshare.26651256
Plichta, D. R., Somani, J., Pichaud, M., Wallace, Z. S., Fernandes, A. D., Perugino, C. A., Lähdesmäki, H., Stone, J. H., Vlamakis, H. C., Chung, D. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14140416
Baud, G., Prasad, A., Ellegaard, K., & Engel, P. (2023) · Figshare · doi:10.6084/m9.figshare.24779172
Muller, E., Algavi, Y. M., & Borenstein, E. (2021) · Figshare · doi:10.6084/m9.figshare.16800607
Dinu, L.-D., Vamanu, E., & Avram, I. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_7
Leveraging machine learning to unravel drug–microbiome interactions in the gut
Wu, K., Li, C., Wang, R., Zhang, C., Geng, H., Zhou, X., He, X., Yang, Y., Lu, D., & Li, F. (2025) · Health engineering. · doi:10.26599/he.2026.9460012
Machine Learning and Multi-omics Integration Approaches for Human Microbiome Data
Choudhury, A., Ortiz, P. S., & Scano, C. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_8 · Cited by 1
Kafoor, N. F. A., & Elbadawi, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.23.701358
“Another possible explanation is that glycoside hydrolase-mediated depletion may follow lactone ring-targeting pathways, similar to the cardiac glycoside reductase (CGR) enzyme in Eggerthella lenta DSM2243 (also known as the ATCC25559 strain) [49].”
Ma, Y., & Liu, L. (2026) · PeerJ Computer Science · doi:10.7717/peerj-cs.3662
Oñate, F. P. (2018) · theses.fr (ABES) · doi:10.70675/88df14a5z15aaz45aezac37z2a096f79eef8
“De même, il a été montré que certains patients sont porteurs d’une sous-espèce d’Eggerthella lenta qui produit une molécule rendant inefficace la digoxine [58], un médicament utilisé pour traiter des maladies cardiaques.”
BackgroundThe microbiome and pharmacotherapy: from mechanisms to consequences
Jourová, L., Anzenbacherová, E., & Anzenbacher, P. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2026.001
The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies
Zhang, L., Samarkhazan, H. S., almajidi, Y., & Refatovich, G. R. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-00972-2
Oh, Y., Lee, J., Um, S., & Kim, S. H. (2026) · Natural Product Reports · doi:10.1039/d6np00039h · Cited by 3
Deshmukh, A. R., Mehta, N. B., Joshi, G. S., & Sawant, P. S. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20261967
Dudzińska, K., Kaftan, A., Plenikowski, J., Kahsin, A., Kacprzak, S., Greluk, A., Żuk, J., Ciszewski, W., Jurewicz, A., & Plenikowska, Z. (2026) · Humanities & Social Sciences Reviews · doi:10.18510/hssr.2026.14126
“This is largely due to small study populations and a significant proportion of preclinical (animal-based) studies (Spanogiannopoulos et al., 2016; Haiser et al., 2013).”
Virtual special section: Gut microbiota in drug metabolism
Jeong, H. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100364
Nagao, I., & Kim, H. J. (2026) · npj Biomedical Innovations. · doi:10.1038/s44385-026-00099-1 · Cited by 1
“C h i p m o d e l s f o r m o d e li n g i n t e s t i n a l fi r s t - p a ss d r u g m e t a b o li s m . clinically relevant microbial reactions, including E. lenta -dependent digoxin inactivation and β -glucuronidase-dependent reactivation of irinotecan metabolites, vary among patients 26,93 .”
Eggerthella lenta: metabolism, pathogenesis and therapeutic implications
Rock, R. R., Zhang, S., Noecker, C. A., & Turnbaugh, P. J. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01344-5 · Cited by 2
“The arginine-derived metabolites citrulline 14 and agmatine 3 can also be utilized to support E. lenta growth.”
InfluentialSelf-citationSong, X., Wang, W., Yang, J., Xinning, L., & Ji, W. (2026) · Microorganisms · doi:10.3390/microorganisms14081744
“Microbial inactivation of digoxin and levodopa has been reported previously [103,104].”
Microbiome: Artifacts in forensic toxicology qualitative and quantitative analysis
Dinis‐Oliveira, R. J., Martins, I. M., Costa, J. G., Freitas, A. R., Remião, F., & Oliveira, N. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40634-8.00018-0
Slastennikova, A., Folz, J. S., Aichinger, G., & Sturla, S. J. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c04575
Bi, Y., Song, W., Glymenaki, M., Hu, J., Li, X., Huang, H., Peng, Y., Ni, S., Haonon, O., Liu, Z., et al. (2026) · iMeta · doi:10.1002/imt2.70144 · Cited by 2
Araújo, G., Domingues, S., Silva, G., & Lima, T. (2026) · Metabolites · doi:10.3390/metabo16090602 · Cited by 1
Zhao, Z., Gong, S., Liu, C., Wen, J., & Zhou, T. (2026) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000211
The microbiota at the interface of environmental toxicants and the brain
Matsuzaki, R., Caudle, W. M., & Sampson, T. R. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.08.002
Das Mikrobiom als verborgener Regulator
Bäumer, L. (2026) · BIOspektrum · doi:10.1007/s12268-026-2804-x
He, Z., Zhou, F., Hao, Y., Fan, B., Tong, J., Guo, Z., Wang, F., & Ma, P. (2026) · Food Nutrition · doi:10.1016/j.fnutr.2026.100087
Composition and Function of the Human Gut Microbiome
Hitch, T. C. A., & Clavel, T. (2026) · Springer eBooks · doi:10.1007/978-3-032-26410-7_2
When microbial drug metabolism becomes a drug disposition variable
Lewandowski, R. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100407
Gut Microbial Metabolism Inactivates Trifluridine and Drives Loss of Anticancer Efficacy
Ahmad, S., Igbalaye, J. O., Perez, V., Wenning, E., Gauthier, S., Ridlon, J. M., & Irudayaraj, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00329
Drug–microbiome–host interactions: antimicrobial effects of non-antibiotic compounds
de la Cuesta‐Zuluaga, J., Patil, K. R., & Maier, L. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01258-w
Kourti, M., Zacharioudakis, E., Kolnagou, A., Evripidou, I., & Kontoghiorghes, G. J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091157
“Dietary factors can further modify this interaction, showing how the microbiota and its by-products, nutrients, and drug metabolism can converge to influence patient-specific drug exposure pharmacology [101–111].”
Haga, S. B. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.1953547
“Well-established examples include reduction of digoxin (Haiser et al., 2013; Kumar et al., 2018), bacterial activation of the prodrug sulfasalazine in the colon (Peppercorn and Goldman, 1972), and microbial metabolism of levodopa (Maini Rekdal et al., 2019), each of which alters drug…”
Role of the Gut Microbiome in Natural and Synthetic Drug Efficacy and Safety: A Narrative Review
Villoch-Rosado, R., Acosta, D., Morales-Santiago, L., González-Tardí, I. M., Medina-Rodríguez, O., Ríos, K., Agront-Medina, I., Alvarado-Andino, A. E., Báez-Rodríguez, L. A., Calderón-Nuñez, A., et al. (2026) · Applied Microbiology · doi:10.3390/applmicrobiol6100113
“Rather, expression of the cgr operon is strongly influenced by dietary arginine availability, illustrating how host diet, microbial gene regulation, and pharmacology interact to determine therapeutic efficacy [52,146,147].”
Engineering Oral Nanoparticles: Navigating Biological Barriers in the Gastrointestinal Tract
Wen, A. C. A., Chen, X., & Zhang, W. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04211-3 · Cited by 1
“For example, Eggerthella lenta inactivates digoxin, reducing systemic exposure [143, 144], while microbial metabolism of L-dopa and certain statins contributes to interindividual variability in therapeutic response [145].”
Deepika, D., Bharti, K., Brull, J., Sabuz, Ó., Musengi, Y., & Kumar, V. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1840947
“Specifically, digoxin is reduced to its inactive metabolite dihydrodigoxin, which loses its ability to bind to the Na+/K + ATPase pocket, diminishing its therapeutic efficacy (Haiser et al., 2013; Haiser et al., 2014).”
Zhao, Y., Peng, C., Xia, Y., Dong, T., Xu, J., Shan, X., Zhong, X., Xue, J., Bing, Z., Li, P., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.09.003 · Cited by 1
Computational approaches to predicting xenobiotic metabolism by the human gut microbiota
Kolodnitsky, A. S., Lagunin, A. A., & Poroikov, V. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2738611
Pharmacomicrobiomics-driven targeted drug delivery for precision microbiome modulation
Biswas, A., Ghosh, B., Kumari, P., Rangra, A., Chowdhury, K., & Kumar, A. A. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00666-2
No strain, no gain: within-host bacterial microdiversity and human health
Wojtkowiak, A., Shinfuku, M. S., & Lewin, G. R. (2026) · Infection and Immunity · doi:10.1128/iai.00062-26
“For instance, variation has been shown in the ability of Eggerthella lenta , a member of the human gut microbiota, to metabolize drugs, altering drug efficacy and toxicity (64).”
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.